Press / Medias

Christensenella: the key to unlocking gut microbiome-based drug discovery?

Jan 2, 2019

LNC Therapeutics recently signed an exclusive license agreement with Cornell University for its Christensenella patent, which covers a recently discovered family of gut bacteria considered to have the potential to unlock a wide range of therapeutic applications for conditions such as obesity and other metabolic diseases. Will this form the foundation for the first drugs using microbiome bacteria? Sally Turner finds out.

 

Clic here to read the full article

In the same category

Press / Medias

EMA & FDA Apply a Similar Mindset When Providing Scientific Advice For Live Biotherapeutic...

Sep 13, 2021

more +
Press / Medias

Bordeaux : un traitement prometteur contre l’obésité développé à base d’une...

Jun 16, 2021

more +
Press / Medias

Le pari gagnant du microbiome

May 24, 2021

more +

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions